Orexo AB (publ) (ORX.ST)
SEK 14.14
(1.73%)
SEK 14.14
(1.73%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 473.8 Million SEK | -12.19% |
| 2022 | 539.6 Million SEK | -1.98% |
| 2021 | 550.5 Million SEK | 89.18% |
| 2020 | 291 Million SEK | -15.48% |
| 2019 | 344.3 Million SEK | 7.39% |
| 2018 | 320.6 Million SEK | 0.44% |
| 2017 | 319.2 Million SEK | -19.76% |
| 2016 | 397.8 Million SEK | -19.53% |
| 2015 | 494.33 Million SEK | 0.12% |
| 2014 | 493.76 Million SEK | 374.4% |
| 2013 | 104.08 Million SEK | -8.36% |
| 2012 | 113.57 Million SEK | -0.82% |
| 2011 | 114.51 Million SEK | 21.28% |
| 2010 | 94.42 Million SEK | 18.37% |
| 2009 | 79.76 Million SEK | 738.78% |
| 2008 | 9.51 Million SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| 2006 | - SEK | 0.0% |
| 2005 | - SEK | 0.0% |
| 2004 | - SEK | 0.0% |
| 2003 | - SEK | 0.0% |
| 2002 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 522 Million SEK | 10.17% |
| 2024 Q2 | 483 Million SEK | -7.47% |
| 2024 Q3 | 573.8 Million SEK | 20.29% |
| 2023 FY | 473.8 Million SEK | -12.19% |
| 2023 Q1 | 530.4 Million SEK | -1.7% |
| 2023 Q3 | 478.7 Million SEK | -7.43% |
| 2023 Q4 | 473.8 Million SEK | -1.02% |
| 2023 Q2 | 517.1 Million SEK | -2.51% |
| 2022 Q1 | 546.9 Million SEK | -0.65% |
| 2022 FY | 539.6 Million SEK | -1.98% |
| 2022 Q4 | 539.6 Million SEK | -0.44% |
| 2022 Q2 | 544.3 Million SEK | -0.48% |
| 2022 Q3 | 542 Million SEK | -0.42% |
| 2021 Q2 | 554.5 Million SEK | 0.14% |
| 2021 Q1 | 553.7 Million SEK | 90.27% |
| 2021 FY | 550.5 Million SEK | 89.18% |
| 2021 Q4 | 550.5 Million SEK | -0.42% |
| 2021 Q3 | 552.8 Million SEK | -0.31% |
| 2020 Q3 | 287.4 Million SEK | -1.71% |
| 2020 Q4 | 291 Million SEK | 1.25% |
| 2020 Q1 | 323.9 Million SEK | -5.93% |
| 2020 Q2 | 292.4 Million SEK | -9.73% |
| 2020 FY | 291 Million SEK | -15.48% |
| 2019 Q1 | 386.2 Million SEK | 20.46% |
| 2019 FY | 344.3 Million SEK | 7.39% |
| 2019 Q4 | 344.3 Million SEK | -1.35% |
| 2019 Q3 | 349 Million SEK | -9.14% |
| 2019 Q2 | 384.1 Million SEK | -0.54% |
| 2018 Q3 | 320.2 Million SEK | 0.13% |
| 2018 Q1 | 462.7 Million SEK | 44.96% |
| 2018 Q2 | 319.8 Million SEK | -30.88% |
| 2018 FY | 320.6 Million SEK | 0.44% |
| 2018 Q4 | 320.6 Million SEK | 0.12% |
| 2017 Q4 | 319.2 Million SEK | -6.28% |
| 2017 Q3 | 340.6 Million SEK | 0.18% |
| 2017 Q2 | 340 Million SEK | 0.18% |
| 2017 FY | 319.2 Million SEK | -19.76% |
| 2017 Q1 | 339.4 Million SEK | -14.68% |
| 2016 FY | 397.8 Million SEK | -19.53% |
| 2016 Q4 | 397.8 Million SEK | -19.81% |
| 2016 Q3 | 496.1 Million SEK | 0.12% |
| 2016 Q2 | 495.5 Million SEK | 0.12% |
| 2016 Q1 | 494.9 Million SEK | 0.11% |
| 2015 Q4 | 494.33 Million SEK | 0.13% |
| 2015 Q2 | 493.1 Million SEK | -0.6% |
| 2015 Q1 | 496.1 Million SEK | 0.47% |
| 2015 FY | 494.33 Million SEK | 0.12% |
| 2015 Q3 | 493.7 Million SEK | 0.12% |
| 2014 Q2 | 496 Million SEK | 61.99% |
| 2014 Q1 | 306.2 Million SEK | 194.19% |
| 2014 Q3 | 496.1 Million SEK | 0.02% |
| 2014 Q4 | 493.76 Million SEK | -0.47% |
| 2014 FY | 493.76 Million SEK | 374.4% |
| 2013 Q2 | 469.7 Million SEK | 95.38% |
| 2013 FY | 104.08 Million SEK | -8.36% |
| 2013 Q4 | 104.08 Million SEK | 70.9% |
| 2013 Q3 | 60.9 Million SEK | -87.03% |
| 2013 Q1 | 240.4 Million SEK | 111.67% |
| 2012 Q4 | 113.57 Million SEK | -67.25% |
| 2012 Q3 | 346.8 Million SEK | -13.3% |
| 2012 FY | 113.57 Million SEK | -0.82% |
| 2012 Q1 | 189.5 Million SEK | 65.48% |
| 2012 Q2 | 400 Million SEK | 111.08% |
| 2011 FY | 114.51 Million SEK | 21.28% |
| 2011 Q4 | 114.51 Million SEK | -49.08% |
| 2011 Q3 | 224.87 Million SEK | -0.53% |
| 2011 Q2 | 226.07 Million SEK | -0.23% |
| 2011 Q1 | 226.6 Million SEK | 139.99% |
| 2010 Q3 | 222.22 Million SEK | -9.19% |
| 2010 Q4 | 94.42 Million SEK | -57.51% |
| 2010 FY | 94.42 Million SEK | 18.37% |
| 2010 Q1 | 57.11 Million SEK | -28.4% |
| 2010 Q2 | 244.7 Million SEK | 328.43% |
| 2009 FY | 79.76 Million SEK | 738.78% |
| 2009 Q3 | 71 Million SEK | 0.0% |
| 2009 Q4 | 79.76 Million SEK | 12.34% |
| 2008 Q4 | 9.51 Million SEK | 0.0% |
| 2008 FY | 9.51 Million SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| 2006 FY | - SEK | 0.0% |
| 2005 FY | - SEK | 0.0% |
| 2004 FY | - SEK | 0.0% |
| 2003 FY | - SEK | 0.0% |
| 2002 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 8.8 Million SEK | -5284.091% |
| Enzymatica AB (publ) | 26.1 Million SEK | -1715.117% |
| Enorama Pharma AB (publ) | 436 Thousand SEK | -108569.725% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | -2402.641% |
| Moberg Pharma AB (publ) | 4.73 Million SEK | -9902.111% |
| Nanexa AB (publ) | 4.03 Million SEK | -11650.992% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Probi AB (publ) | 53.79 Million SEK | -780.718% |
| Swedencare AB (publ) | 1.65 Billion SEK | 71.434% |
| Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 97.687% |
| Toleranzia AB | 850 Thousand SEK | -55641.176% |
| Vivesto AB | 8.16 Million SEK | -5700.686% |